ABBV vs QUCY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.
Compare Another Pair
Related Comparisons
ABBV vs QUCY: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and Mainz Biomed N.V. (QUCY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.